Core Insights - The company achieved 66% annual revenue growth driven by Auvelity's rapid uptake, surpassing $500 million in net sales in its third full year of launch [1] - Auvelity's outperformance is attributed to its distinct clinical profile and fast onset of action, allowing it to grow 42% year-over-year while the broader antidepressant market remained flat [1] - The primary care prescriber base for Auvelity has expanded, now representing approximately one-third of all prescribers and is the fastest-growing segment [1] Sales and Market Expansion - A major sales force expansion has been initiated to approximately 600 representatives to support continued growth in Major Depressive Disorder (MDD) and prepare for the potential Alzheimer's disease agitation (ADA) launch [1] - Sunosi reported accelerating momentum with 40% fourth-quarter revenue growth, driven by increased depth among existing writers in both the Obstructive Sleep Apnea (OSA) and narcolepsy markets [1] - The company successfully contracted with a third large commercial Group Purchasing Organization (GPO) for Cymbravo, enabling negotiations with all major commercial payers and Pharmacy Benefit Managers (PBMs) to improve market access [1] Strategic Acquisitions - The company acquired AXS-17, a novel GABA-A modulator, to leverage its expertise in Central Nervous System (CNS) and existing safety data for a new development program in epilepsy [1]